COVID-19 - Evaluation von Biomarkern im klinischen Verlauf der Erkrankung

Hillebrecht, Anke

dc.contributor.advisor	Blaschke-Steinbrecher, Sabine Prof. Dr.
dc.contributor.author	Hillebrecht, Anke
dc.date.accessioned	2022-03-22T15:41:03Z
dc.date.available	2022-04-06T00:50:14Z
dc.date.issued	2022-03-22
dc.identifier.uri	http://resolver.sub.uni-goettingen.de/purl?ediss-11858/13945
dc.identifier.uri	http://dx.doi.org/10.53846/goediss-9100
dc.language.iso	deu	de
dc.rights.uri	http://creativecommons.org/licenses/by/4.0/
dc.subject.ddc	610	de
dc.title	COVID-19 - Evaluation von Biomarkern im klinischen Verlauf der Erkrankung	de
dc.type	doctoralThesis	de
dc.contributor.referee	Blaschke-Steinbrecher, Sabine Prof. Dr.
dc.date.examination	2022-03-30	de
dc.description.abstracteng	The course of serological and laboratory biomarkers during the phase of inpatient treatment of COVID-19 patients was investigated. Data from a total of n=47 patients were retrospectively analyzed. These included selected vital signs, laboratory parameters, and serial RT-qPCR and antibody diagnostics in addition to age and sex. Higher respiratory rates were highly significantly (p<0.001) associated with higher COVID-19 disease severity. The same was true for the presence of dyspnea (p<0.001) and the CRB-65 score obtained in the emergency department (p<0.001). A significant association (p=0.05) was shown for the presence of fever with higher COVID-19 disease severity scores. In laboratory diagnostics, highly significant differences were found between COVID-19 disease severity and the level of leukocyte and lymphocyte counts (p<0.007) as well as plasma concentrations of CRP (p<0.001), PCT (p<0.001), LDH (p<0.001) and D-dimer (p<0.02). Negative SARS-CoV-2 PCR tests were obtained significantly later in patients with higher COVID-19 disease severity than in patients with milder courses. The peak of both SARS-CoV-2 IgG and SARS-CoV-2 IgA antibodies was found to occur around day 20 after symptom onset. Time points of SARS-CoV-2 IgG and IgA seroconversion were found to be significantly associated with BMI class (p<0.001). By assessment of clinical disease severity and laboratory as well as virological bio-markers risk groups of COVID-19 patients could be identified in the ED thus helping to adjust risk-adapted treatment strategies.	de
dc.contributor.coReferee	Groß, Uwe Prof. Dr.
dc.subject.eng	SARS-CoV-2	de
dc.subject.eng	COVID-19	de
dc.subject.eng	WHO disease activity score	de
dc.subject.eng	anti-SARS-CoV-2 antibodies	de
dc.subject.eng	serology	de
dc.identifier.urn	urn:nbn:de:gbv:7-ediss-13945-6
dc.affiliation.institute	Medizinische Fakultät	de
dc.subject.gokfull	Medizin (PPN619874732)	de
dc.subject.gokfull	:Medizinische Mikrobiologie / Medizinische Virologie / Medizinische Mykologie / Infektionskrankheiten / Hygiene / Impfung / Parasitologie / Tropenmedizin - Allgemein- und Gesamtdarstellungen (PPN619875356)	de
dc.description.embargoed	2022-04-06	de
dc.identifier.ppn	1797016709

Dateien

Name:HillebrechtCOVID19.pdf

Größe:1.815Mb

Format:PDF

Öffnen

Name:: HillebrechtCOVID19.pdf
Größe:: 1.815Mb
Format:: PDF

Öffnen

Das Dokument erscheint in:

Human- und Zahnmedizin [2872]

Zur Kurzanzeige